<p>根据雷蒙德·詹姆斯金融公司最近向证券交易委员会（SEC）提交的 13F 表格，该公司在第四季度收购了 Vaxcyte, Inc.（NASDAQ:PCVX - 免费报告）的新股份。这家机构投资者收购了 264,704 股该公司的股票，价值约为 21,669,000 美元。截至其最近向证券交易委员会（SEC）提交的文件，雷蒙德·詹姆斯金融公司持有 Vaxcyte 0.21% 的股份。</p>
<ul>
<li>MarketBeat 周报 – 4/17 - 4/21</li>
</ul>
<p>其他一些对冲基金也调整了对 PCVX 的持股。Whipplewood Advisors LLC 在第四季度以约 28,000 美元的价格收购了 Vaxcyte 的新股份。Smartleaf Asset Management LLC 在第四季度将其在 Vaxcyte 的持股增加了 188.4%。Smartleaf Asset Management LLC 现在拥有 398 股该公司的股票，价值 33,000 美元，此前在该期间又购买了 260 股。Blue Trust Inc.在第四季度将其在 Vaxcyte 的持股增加了 100.0%。Blue Trust Inc.现在拥有 742 股该公司的股票，价值 61,000 美元，此前在该期间又收购了 371 股。Assetmark Inc.在第四季度将其在 Vaxcyte 的持股增加了 77,500.0%。Assetmark Inc.现在拥有 776 股该公司的股票，价值 64,000 美元，此前在该期间又收购了 775 股。最后，Meeder Asset Management Inc.在第三季度将其在 Vaxcyte 的持股增加了 1,007.9%。Meeder Asset Management Inc.现在拥有 698 股该公司的股票，价值 80,000 美元，此前在该期间又收购了 635 股。96.78% 的股票目前由机构投资者和对冲基金持有。</p>
<h2>内部交易活动</h2>
<p>在其他消息中，首席财务官 Andrew Guggenhime 在 12 月 18 日（星期三）出售了 8,000 股公司的股票。股票以平均价格 88.78 美元出售，总价值为 710,240.00 美元。交易完成后，首席财务官现在拥有 109,491 股公司的股票，价值 9,720,610.98 美元。这笔交易代表其持股减少了 6.81%。该交易已在向 SEC 的法律文件中披露，相关信息可通过此链接获取。此外，董事 Teri Loxam 在 1 月 15 日（星期三）出售了 6,250 股公司的股票。股票以平均价格 85.11 美元出售，总价值为 531,937.50 美元。交易完成后，该董事现在拥有 7,175 股公司的股票，价值约 610,664.25 美元。这笔交易代表其持股减少了 46.55%。该销售的披露信息可以在这里找到。过去一个季度，内部人士共出售了 54,250 股公司股票，价值 4,550,258 美元。当前 3.10% 的股票由公司内部人士持有。</p>
<h2>Vaxcyte 股票上涨 1.8%</h2>
<ul>
<li>仍有 50% 的上涨空间，华尔街对 Vaxcyte 的看法正确</li>
</ul>
<p>PCVX 股票在周五开盘价为 74.37 美元。该公司的市值为 95.8 亿美元，市盈率为-16.17，贝塔值为 1.02。该公司的 50 日移动平均线为 82.24 美元，200 日移动平均线为 94.36 美元。Vaxcyte, Inc.的 12 个月低点为 58.10 美元，12 个月高点为 121.06 美元。</p>
<p>Vaxcyte（NASDAQ:PCVX - 获取免费报告）最近在 2 月 25 日（星期二）发布了其财报。该公司报告本季度每股收益为-1.02 美元，超出市场共识预期的-1.16 美元，超出幅度为 0.14 美元。研究分析师平均预测 Vaxcyte, Inc.在当前财政年度的每股收益为-4.21 美元。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>为什么投资者突然对 Vaxcyte 感到兴奋</li>
</ul>
<p>几位分析师最近对该公司进行了评论。高盛集团在 12 月 20 日（星期五）发布的报告中开始覆盖 Vaxcyte。他们对该股票给予了 “买入” 评级，并设定了 135.00 美元的目标价。Guggenheim 在周三重申了 “买入” 评级，并设定了 160.00 美元的目标价。最后，Needham &amp; Company LLC 在 2 月 26 日（星期三）重申了 “买入” 评级，并设定了 140.00 美元的目标价。九位研究分析师对该股票给予了买入评级，根据 MarketBeat.com 的数据，Vaxcyte 目前的平均评级为 “买入”，共识目标价为 147.50 美元。</p>
<p><strong>查看我们对 Vaxcyte 的最新股票分析</strong></p>
<h2>Vaxcyte 公司简介</h2>
<p>（免费报告）</p>
<p>Vaxcyte, Inc.是一家临床阶段的生物技术疫苗公司，开发新型蛋白质疫苗以预防或治疗细菌感染性疾病。其主要疫苗候选产品是 VAX-24，一种 24 价的研究性肺炎球菌结合疫苗，用于预防侵袭性肺炎球菌疾病。该公司还开发 VAX-31 以保护新出现的菌株，并帮助应对抗生素耐药性；VAX-A1，一种新型结合疫苗候选产品，用于预防 A 组链球菌引起的疾病；VAX-PG，一种新型蛋白质疫苗候选产品，针对导致牙周炎的关键病原体；以及 VAX-GI，用于预防细菌性疾病志贺氏菌。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票超过 Vaxcyte</li>
<li>市值计算器：如何计算市值</li>
<li>忽略报告，苹果不会在 iOS 18.3 中安装 Starlink</li>
<li>资产配置：成功投资组合的关键。你在关注自己的投资组合吗？</li>
<li>Casey 的上升趋势依然强劲——新高在望</li>
<li>现在购买的三只巨型成长股</li>
<li>台湾半导体在美国的巨大举动——股票影响在前</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UENWWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UENWWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Vaxcyte 吗？</h2>
<p>在考虑 Vaxcyte 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及他们推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Vaxcyte 并不在名单上。</p>
<p>虽然 Vaxcyte 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

瑞杰金融

PCVX

<p>根据其向美国证券交易委员会（SEC）提交的文件，瑞杰金融（Raymond James Financial Inc.）在第四季度收购了 Vaxcyte, Inc.（NASDAQ:PCVX）约 2167 万美元的新股份。该公司购买了 264,704 股，代表 0.21% 的持股比例。其他对冲基金也调整了在 Vaxcyte 的持仓。内部交易包括首席财务官安德鲁·古根海姆（Andrew Guggenhime）和董事特里·洛克萨姆（Teri Loxam）出售股份。Vaxcyte 的股票目前交易价格为 74.37 美元，分析师预测其将实现增长，并设定目标价格在 135.00 美元至 160.00 美元之间</p>

<p>Raymond James Financial Inc. acquired a new stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 264,704 shares of the company's stock, valued at approximately $21,669,000. Raymond James Financial Inc. owned 0.21% of Vaxcyte as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>根据雷蒙德·詹姆斯金融公司最近向证券交易委员会（SEC）提交的 13F 表格，该公司在第四季度收购了 Vaxcyte, Inc.（NASDAQ:PCVX - 免费报告）的新股份。这家机构投资者收购了 264,704 股该公司的股票，价值约为 21,669,000 美元。截至其最近向证券交易委员会（SEC）提交的文件，雷蒙德·詹姆斯金融公司持有 Vaxcyte 0.21% 的股份。</p>
</div><ul>
<li>MarketBeat Week in Review – 4/17 - 4/21</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周报 – 4/17 - 4/21</li>
</ul>
</div><p>A number of other hedge funds have also modified their holdings of PCVX. Whipplewood Advisors LLC acquired a new position in shares of Vaxcyte in the fourth quarter valued at about $28,000. Smartleaf Asset Management LLC increased its holdings in shares of Vaxcyte by 188.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock valued at $33,000 after purchasing an additional 260 shares during the period. Blue Trust Inc. grew its holdings in Vaxcyte by 100.0% during the fourth quarter. Blue Trust Inc. now owns 742 shares of the company's stock worth $61,000 after acquiring an additional 371 shares during the period. Assetmark Inc. grew its holdings in Vaxcyte by 77,500.0% during the fourth quarter. Assetmark Inc. now owns 776 shares of the company's stock worth $64,000 after acquiring an additional 775 shares during the period. Finally, Meeder Asset Management Inc. grew its holdings in Vaxcyte by 1,007.9% during the third quarter. Meeder Asset Management Inc. now owns 698 shares of the company's stock worth $80,000 after acquiring an additional 635 shares during the period. 96.78% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他一些对冲基金也调整了对 PCVX 的持股。Whipplewood Advisors LLC 在第四季度以约 28,000 美元的价格收购了 Vaxcyte 的新股份。Smartleaf Asset Management LLC 在第四季度将其在 Vaxcyte 的持股增加了 188.4%。Smartleaf Asset Management LLC 现在拥有 398 股该公司的股票，价值 33,000 美元，此前在该期间又购买了 260 股。Blue Trust Inc.在第四季度将其在 Vaxcyte 的持股增加了 100.0%。Blue Trust Inc.现在拥有 742 股该公司的股票，价值 61,000 美元，此前在该期间又收购了 371 股。Assetmark Inc.在第四季度将其在 Vaxcyte 的持股增加了 77,500.0%。Assetmark Inc.现在拥有 776 股该公司的股票，价值 64,000 美元，此前在该期间又收购了 775 股。最后，Meeder Asset Management Inc.在第三季度将其在 Vaxcyte 的持股增加了 1,007.9%。Meeder Asset Management Inc.现在拥有 698 股该公司的股票，价值 80,000 美元，此前在该期间又收购了 635 股。96.78% 的股票目前由机构投资者和对冲基金持有。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部交易活动</h2>
</div><p>In other news, CFO Andrew Guggenhime sold 8,000 shares of the firm's stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $88.78, for a total value of $710,240.00. Following the transaction, the chief financial officer now owns 109,491 shares in the company, valued at $9,720,610.98. This trade represents a 6.81 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Teri Loxam sold 6,250 shares of the firm's stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total value of $531,937.50. Following the completion of the transaction, the director now owns 7,175 shares in the company, valued at approximately $610,664.25. This trade represents a 46.55 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 54,250 shares of company stock worth $4,550,258 over the last quarter. 3.10% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他消息中，首席财务官 Andrew Guggenhime 在 12 月 18 日（星期三）出售了 8,000 股公司的股票。股票以平均价格 88.78 美元出售，总价值为 710,240.00 美元。交易完成后，首席财务官现在拥有 109,491 股公司的股票，价值 9,720,610.98 美元。这笔交易代表其持股减少了 6.81%。该交易已在向 SEC 的法律文件中披露，相关信息可通过此链接获取。此外，董事 Teri Loxam 在 1 月 15 日（星期三）出售了 6,250 股公司的股票。股票以平均价格 85.11 美元出售，总价值为 531,937.50 美元。交易完成后，该董事现在拥有 7,175 股公司的股票，价值约 610,664.25 美元。这笔交易代表其持股减少了 46.55%。该销售的披露信息可以在这里找到。过去一个季度，内部人士共出售了 54,250 股公司股票，价值 4,550,258 美元。当前 3.10% 的股票由公司内部人士持有。</p>
</div><h2>Vaxcyte Trading Up 1.8 %</h2>
<div class="lb-trans"><h2>Vaxcyte 股票上涨 1.8%</h2>
</div><ul>
<li>Still 50% Upside To Go, Wall Street Is Getting Vaxcyte Right</li>
</ul>
<div class="lb-trans"><ul>
<li>仍有 50% 的上涨空间，华尔街对 Vaxcyte 的看法正确</li>
</ul>
</div><p>Shares of PCVX stock opened at $74.37 on Friday. The company has a market capitalization of $9.58 billion, a P/E ratio of -16.17 and a beta of 1.02. The business's 50 day moving average is $82.24 and its two-hundred day moving average is $94.36. Vaxcyte, Inc. has a 12-month low of $58.10 and a 12-month high of $121.06.</p>
<div class="lb-trans"><p>PCVX 股票在周五开盘价为 74.37 美元。该公司的市值为 95.8 亿美元，市盈率为-16.17，贝塔值为 1.02。该公司的 50 日移动平均线为 82.24 美元，200 日移动平均线为 94.36 美元。Vaxcyte, Inc.的 12 个月低点为 58.10 美元，12 个月高点为 121.06 美元。</p>
</div><p>Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.14. On average, research analysts predict that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Vaxcyte（NASDAQ:PCVX - 获取免费报告）最近在 2 月 25 日（星期二）发布了其财报。该公司报告本季度每股收益为-1.02 美元，超出市场共识预期的-1.16 美元，超出幅度为 0.14 美元。研究分析师平均预测 Vaxcyte, Inc.在当前财政年度的每股收益为-4.21 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>Why Investors Are Suddenly Excited About Vaxcyte</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么投资者突然对 Vaxcyte 感到兴奋</li>
</ul>
</div><p>Several analysts recently commented on the company. The Goldman Sachs Group assumed coverage on Vaxcyte in a report on Friday, December 20th. They set a &#34;buy&#34; rating and a $135.00 target price on the stock. Guggenheim reaffirmed a &#34;buy&#34; rating and set a $160.00 target price on shares of Vaxcyte in a report on Wednesday. Finally, Needham &amp; Company LLC reaffirmed a &#34;buy&#34; rating and set a $140.00 target price on shares of Vaxcyte in a report on Wednesday, February 26th. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Vaxcyte currently has an average rating of &#34;Buy&#34; and a consensus target price of $147.50.</p>
<div class="lb-trans"><p>几位分析师最近对该公司进行了评论。高盛集团在 12 月 20 日（星期五）发布的报告中开始覆盖 Vaxcyte。他们对该股票给予了 “买入” 评级，并设定了 135.00 美元的目标价。Guggenheim 在周三重申了 “买入” 评级，并设定了 160.00 美元的目标价。最后，Needham &amp; Company LLC 在 2 月 26 日（星期三）重申了 “买入” 评级，并设定了 140.00 美元的目标价。九位研究分析师对该股票给予了买入评级，根据 MarketBeat.com 的数据，Vaxcyte 目前的平均评级为 “买入”，共识目标价为 147.50 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Vaxcyte</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Vaxcyte 的最新股票分析</strong></p>
</div><h2>Vaxcyte Profile</h2>
<div class="lb-trans"><h2>Vaxcyte 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.</p>
<div class="lb-trans"><p>Vaxcyte, Inc.是一家临床阶段的生物技术疫苗公司，开发新型蛋白质疫苗以预防或治疗细菌感染性疾病。其主要疫苗候选产品是 VAX-24，一种 24 价的研究性肺炎球菌结合疫苗，用于预防侵袭性肺炎球菌疾病。该公司还开发 VAX-31 以保护新出现的菌株，并帮助应对抗生素耐药性；VAX-A1，一种新型结合疫苗候选产品，用于预防 A 组链球菌引起的疾病；VAX-PG，一种新型蛋白质疫苗候选产品，针对导致牙周炎的关键病原体；以及 VAX-GI，用于预防细菌性疾病志贺氏菌。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Vaxcyte</li>
<li>Market Cap Calculator: How to Calculate Market Cap</li>
<li>Ignore Reports, Apple Won't Install Starlink with iOS 18.3</li>
<li>Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?</li>
<li>Casey’s Uptrend Remains Strong—New Highs on the Horizon</li>
<li>3 Monster Growth Stocks to Buy Now</li>
<li>Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Vaxcyte</li>
<li>市值计算器：如何计算市值</li>
<li>忽略报告，苹果不会在 iOS 18.3 中安装 Starlink</li>
<li>资产配置：成功投资组合的关键。你在关注自己的投资组合吗？</li>
<li>Casey 的上升趋势依然强劲——新高在望</li>
<li>现在购买的三只巨型成长股</li>
<li>台湾半导体在美国的巨大举动——股票影响在前</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UENWWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=PCVX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Vaxcyte Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Vaxcyte 吗？</h2>
</div><p>Before you consider Vaxcyte, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Vaxcyte 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及他们推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Vaxcyte 并不在名单上。</p>
</div><p>While Vaxcyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Vaxcyte 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

瑞杰金融公司在 Vaxcyte 公司（纳斯达克股票代码：PCVX）持有 2167 万美元的头寸